Biopharmaceutical Leaders Gather at Veeva R&D and Quality Summit in Europe to Drive Innovation
The biopharmaceutical industry is set to witness a significant gathering at the upcoming Veeva R&D and Quality Summit Europe, which is scheduled for June 4-5 in Madrid, Spain. Veeva Systems (NYSE: VEEV) has announced its lineup of eminent speakers, including leaders from renowned companies such as Bayer, Lonza, MSD, Novo Nordisk, Recipharm, and Teva, who will shine a light on the transformative role of AI and connected platforms in the advancement of drug development and manufacturing processes.
The summit, one of Europe's largest meetings for life sciences professionals, is expected to attract over 1,400 attendees and feature more than 100 sessions aimed at delving into crucial developments in clinical research, regulatory affairs, safety measures, and quality assurance. As the biopharma sector continues to evolve, the need for collaboration and innovation has never been greater.
At the opening conference, participants will engage with key insights from leaders in the industry. Notable speakers will include Rik Van Mol, Senior Vice President of R&D and Quality at Novo Nordisk, and Avril England, General Manager of Veeva Vault. Their discussion will focus on streamlining the development and manufacturing of new drugs and therapies, bridging traditional practices with cutting-edge innovations.
Among the sessions scheduled, Bayer is set to share its strategies for optimizing clinical infrastructure with a customer-centric approach to work with research centers. Lonza, a leading contract development and manufacturing organization (CDMO), will discuss how the constantly evolving industry landscape is reshaping quality management among partners. MSD will explore innovations in pharmacovigilance operations showcasing how reliable databases can lead to higher efficiency.
Novo Nordisk is eager to present its techniques for accelerating clinical trials and launching new products by integrating business and IT in the Veeva Development Cloud, thereby enhancing collaboration and data consistency. Teva will emphasize how innovation, agility, and a data-driven mindset are enabling the company to navigate regulatory changes and enhance operational efficiency.
Rik Van Mol commented, "An innovative mindset and a strong community are crucial for transforming the way we deliver medications to patients. At the Veeva R&D and Quality Summit, leaders come together to generate new ideas, share advancements, and collectively forge the industry’s future."
This summit is strictly reserved for life sciences professionals who are keen on advancing their understanding of the impending changes within the biopharmaceutical landscape. Attendees can register and view the detailed agenda on Veeva’s official website.
Veeva Systems is the global leader in cloud software for the life sciences industry. With a commitment to innovation, product excellence, and customer success, Veeva serves over 1,000 clients, including the world's largest biopharma companies and emerging biotech entities. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
This announcement contains forward-looking statements regarding Veeva's products and services and anticipated results or benefits from the utilization of its offerings, some of which are still under development or not yet generally available. These statements are based on Veeva’s current expectations and actual results, availability, and future events may differ materially from those provided in this announcement. Numerous risks could negatively affect our results, including those outlined in our 10-K filing for the fiscal year ending January 31, 2025, found at sec.gov.
The summit, one of Europe's largest meetings for life sciences professionals, is expected to attract over 1,400 attendees and feature more than 100 sessions aimed at delving into crucial developments in clinical research, regulatory affairs, safety measures, and quality assurance. As the biopharma sector continues to evolve, the need for collaboration and innovation has never been greater.
At the opening conference, participants will engage with key insights from leaders in the industry. Notable speakers will include Rik Van Mol, Senior Vice President of R&D and Quality at Novo Nordisk, and Avril England, General Manager of Veeva Vault. Their discussion will focus on streamlining the development and manufacturing of new drugs and therapies, bridging traditional practices with cutting-edge innovations.
Among the sessions scheduled, Bayer is set to share its strategies for optimizing clinical infrastructure with a customer-centric approach to work with research centers. Lonza, a leading contract development and manufacturing organization (CDMO), will discuss how the constantly evolving industry landscape is reshaping quality management among partners. MSD will explore innovations in pharmacovigilance operations showcasing how reliable databases can lead to higher efficiency.
Novo Nordisk is eager to present its techniques for accelerating clinical trials and launching new products by integrating business and IT in the Veeva Development Cloud, thereby enhancing collaboration and data consistency. Teva will emphasize how innovation, agility, and a data-driven mindset are enabling the company to navigate regulatory changes and enhance operational efficiency.
Rik Van Mol commented, "An innovative mindset and a strong community are crucial for transforming the way we deliver medications to patients. At the Veeva R&D and Quality Summit, leaders come together to generate new ideas, share advancements, and collectively forge the industry’s future."
This summit is strictly reserved for life sciences professionals who are keen on advancing their understanding of the impending changes within the biopharmaceutical landscape. Attendees can register and view the detailed agenda on Veeva’s official website.
More about Veeva Systems
Veeva Systems is the global leader in cloud software for the life sciences industry. With a commitment to innovation, product excellence, and customer success, Veeva serves over 1,000 clients, including the world's largest biopharma companies and emerging biotech entities. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Future Statements
This announcement contains forward-looking statements regarding Veeva's products and services and anticipated results or benefits from the utilization of its offerings, some of which are still under development or not yet generally available. These statements are based on Veeva’s current expectations and actual results, availability, and future events may differ materially from those provided in this announcement. Numerous risks could negatively affect our results, including those outlined in our 10-K filing for the fiscal year ending January 31, 2025, found at sec.gov.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.